Patients with metastatic colon cancer respond to new combination therapy
In an aggressive disease known for poor response rates, researchers from The University of Texas MD Anderson Cancer Center
found patients with advanced colorectal cancer responded well to a
combination therapy of the drugs vermurafenib, cetuximab and irinotecan.
Source: M. D. Anderson Cancer Center - News Releases - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Colon Cancer | Colorectal Cancer | Erbitux | Texas University